• Low testosterone increases risk of heart disease, diabetes, depression, and early death.

• The TRAVERSE trial (2023) confirmed testosterone therapy does not raise cardiovascular risk.

• Physiologic testosterone therapy does not cause prostate cancer or enlargement.

• Bioidentical testosterone pellets deliver steady levels with fewer side effects.

• The real danger isn’t therapy — it’s doing nothing.

Testosterone supports:

• Muscle and bone strength

• Cognition and focus

• Mood and motivation

• Heart and metabolic health

• Sexual function and confidence

Levels decline about 1–2% per year after age 30, and when they fall below 300 ng/dL, symptoms begin: fatigue, irritability, low libido, and body composition changes.

Low testosterone isn’t just uncomfortable — it’s a metabolic risk factor.

• Men with low T are twice as likely to develop metabolic syndrome.

• They have 30–50% higher cardiovascular mortality (European Heart Journal, 2018).

• Untreated men experience faster cognitive decline and muscle loss.

Ignoring testosterone deficiency shortens both lifespan and healthspan.

In 2014, early flawed studies suggested testosterone might increase heart attacks.
But larger, better-controlled trials — including TRAVERSE (NEJM 2023) and The Testosterone Trials (NEJM 2016) — proved otherwise:

• No increase in heart attacks or strokes.

• Improved blood sugar, cholesterol, and inflammation.

• Better quality of life and vitality.

When prescribed correctly, testosterone therapy is not dangerous — it’s restorative.

The Old Fear

“Testosterone feeds prostate cancer.”

This belief traces back to a 1941 study observing cancer regression after castration — long before modern hormone science and our understanding of androgen receptors.

The Modern Reality

Decades of research now show that physiologic testosterone does not increase prostate cancer risk.
In fact, maintaining healthy testosterone may help reduce inflammation and stabilize prostate tissue.

Key Evidence

1. Snyder et al., NEJM 2016 (The TTrials)

   • No rise in PSA (prostate-specific antigen) or prostate volume in men treated with testosterone vs. placebo.

2. Morgentaler & Traish, European Urology 2009

   • Introduced the Saturation Model: once androgen receptors are full, higher testosterone levels do not further stimulate prostate growth.

3. Mayo Clinic Proceedings 2016; J Clin Endocrinol Metab 2018

   • Large meta-analyses found no link between testosterone therapy and prostate cancer incidence.

4. TRAVERSE Trial, NEJM 2023

   • Over 5,200 men followed for 3 years showed no difference in prostate cancer, urinary retention, or PSA elevation between testosterone and placebo groups.

What About BPH (Prostate Enlargement)?

Low testosterone itself can worsen urinary symptoms by increasing inflammation and reducing muscle tone in the prostate and bladder neck.

Studies in men treated with testosterone show:

• Improved urinary flow and fewer nighttime bathroom trips (J Urol, 2015).

• No abnormal prostate growth beyond normal, age-related changes.

The Bottom Line

Healthy testosterone levels support prostate function — they don’t harm it.

Modern endocrinology now recognizes that low testosterone is a risk factor for aggressive prostate disease, not the cause of it.

Supporting Guidelines

Both the Endocrine Society (2018) and the American Urological Association (2023) affirm:

Testosterone therapy is safe in men without active prostate cancer and does not raise risk when properly monitored.

At Leva Medical, every patient receives baseline and follow-up PSA testing and digital rectal exams to ensure long-term safety and peace of mind.

Men with untreated low testosterone face higher risks of:

• Cardiovascular disease and early death

• Osteoporosis and fractures

• Depression and dementia

• Obesity and diabetes

When testosterone is restored to normal physiologic range, men live longer, stronger, and healthier.

Cardiovascular & Longevity

1. Budoff MJ et al. TRAVERSE Trial: Cardiovascular Safety of Testosterone Therapy. N Engl J Med. 2023;389(4):338–349.

2. Saad F et al. Testosterone Therapy and Mortality in Hypogonadal Men. Eur Heart J. 2018;39(47):4245–4252.

3. Jones TH, Kelly DM. Testosterone and Cardiovascular Risk in Men. Front Horm Res. 2019;53:45–58.

Prostate & Urologic Health

4. Snyder PJ et al. The Testosterone Trials (TTrials) – Prostate Safety Findings. N Engl J Med. 2016;374(7):611–624.

5. Morgentaler A, Traish AM. Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model. Eur Urol. 2009;55(2):310–321.

6. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.

7. Kacker R, et al. The Relationship Between Testosterone Therapy and Benign Prostatic Hyperplasia. J Urol. 2015;194(6):1586–1592.

Metabolism, Mood & Bone

8. Grossmann M, et al. Testosterone and Type 2 Diabetes. Diabetes Care. 2018;41(11):2308–2316.

9. Basaria S, et al. Testosterone and Bone Mineral Density in Aging Men. J Bone Miner Res. 2019;34(11):2045–2052.

10. Cherrier MM, et al. Testosterone Supplementation Improves Memory in Older Men. Neurology. 2005;64(12):2063–2068.

Bioidentical Pellets

11. Glaser RL, Dimitrakakis C. Testosterone Pellets: Long-Term Efficacy and Safety Data in Men. Maturitas. 2012;71(4):373–378.